PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis

Journal of Gastrointestinal Cancer, Год журнала: 2025, Номер 56(1)

Опубликована: Янв. 20, 2025

Язык: Английский

---

Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials

Clinical Oncology, Год журнала: 2024, Номер 36(10), С. e408 - e419

Опубликована: Июль 2, 2024

Язык: Английский

---

Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials

European Journal of Clinical Pharmacology, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 14, 2024

Язык: Английский

---

Immune checkpoint inhibitors plus taxane-based chemotherapy for patients with advanced/metastatic NSCLC: a systematic review and meta-analysis across different PD-L1 expression levels

Expert Review of Anticancer Therapy, Год журнала: 2025, Номер unknown

Опубликована: Янв. 28, 2025

Background Immune checkpoint inhibitors (ICIs) are currently the primary approach for managing NSCLC. However, numerous combination therapies under investigation. Our goal is to investigate overall efficacy and safety of ICIs taxane-based chemotherapy.

Язык: Английский

---

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Янв. 31, 2025

The combination of programmed cell death 1 (PD-1)/programmed ligand (PD-L1) inhibitors with chemotherapy (CT) is currently under evaluation as a first-line treatment for advanced or recurrent endometrial cancer (EC). This study sought to assess the efficacy and safety this therapeutic in patients EC. We performed an exhaustive review randomized controlled trials (RCTs) up September 25, 2024, examining combining PD-1/PD-L1 CT versus alone (or plus placebo) Efficacy was measured by progression-free survival (PFS) overall (OS), while assessed incidence any grade ≥ 3 adverse events (AEs). calculated hazard ratios (HRs) PFS OS, well risk (RRs) AEs, each accompanied 95% confidence intervals (CIs). To evaluate heterogeneity, we employed Cochran's Q test, I2 statistics, prediction (PIs). Trial sequential analysis (TSA) conducted using R Version 4.3.1, STATA 12.0, TSA 0.9.5.10 Beta software. Our incorporated 6 studies, encompassing total 2,954 patients. significantly improved (HR = 0.617, CI: 0.506-0.752; PI: 0.334-1.140) OS 0.774, 0.664-0.902; 0.553-1.083) compared population. Subgroup based on mismatch repair (MMR) status revealed pronounced benefits deficient MMR (dMMR) (PFS: HR 0.344, 0.269-0.438; 0.231-0.510; OS: 0.371, 0.245-0.562; 0.025-5.461) those proficient (pMMR) 0.772, 0.627-0.950; 0.394-1.512; 0.996, 0.692-1.435; 0.021-47.662). Although there no observed difference grades AEs (RR 0.994, 0.982-1.006; 0.978-1.009), elevated group receiving 1.132, 1.023-1.252; 0.836-1.532). EC patients, particularly dMMR. Clinicians can tailor strategies according individual patient characteristics optimize outcomes, remaining alert possibility clinical practice. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024595455.

Язык: Английский

---

Impact of Helicobacter pylori infection status on outcomes among patients with gastric cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Microbial Pathogenesis, Год журнала: 2025, Номер unknown, С. 107407 - 107407

Опубликована: Фев. 1, 2025

Язык: Английский

---

Successful treatment with oxaliplatin and programmed cell death protein 1 inhibitor in recurrent advanced endometrial carcinoma with mismatch repair defects: a case report and literature review

Journal of Chemotherapy, Год журнала: 2025, Номер unknown, С. 1 - 7

Опубликована: Фев. 21, 2025

The incidence of endometrial cancer (EC), a widely prevalent gynecological malignancy, is witnessing global surge. Although early-stage demonstrates promising outcomes, advanced associated with an unfavorable prognosis. Nevertheless, for specific pathological types or molecular subtypes EC, accurate treatment algorithm can lead to favorable Here, we report case stage IVB EC characterized by mucinous differentiation mismatch repair deficiencies (MMRd) who was successfully treated combination oxaliplatin and programmed cell death protein 1 (PD-1) inhibitor. Our findings emphasize the importance conducting typing assessments in individuals recurrent EC. Additionally, combining PD-1 inhibitors may be viable option MMRd. More representative standardized studies are needed consolidate this conclusion.

Язык: Английский

---

Efficacy of PD-(L)1 Inhibition in the Treatment of Endometrial Cancer Across Molecular Classes: A Systematic Review and Meta-analysis

International Journal of Gynecological Cancer, Год журнала: 2025, Номер unknown, С. 101759 - 101759

Опубликована: Март 1, 2025

ObjectivePD-(L)1 inhibitors have shown benefit in mismatch repair-deficient (MMRd) endometrial cancer. However, their efficacy MMR-proficient cancer — comprising POLE-mutated (POLEmut), p53-abnormal (p53abn), and no-specific-molecular-profile (NSMP) molecular classes remains unclear. This systematic review meta-analysis evaluated the of PD-(L)1 inhibitors, as monotherapy or combined with chemotherapy, across four classes.MethodsSystematic searches were conducted Embase, PubMed, Cochrane, Web Science, manual reference lists conference websites. Seven reports on five clinical trials identified, three included meta-analysis. Overall survival progression-free assessed.ResultsIn patients primary advanced recurrent MMRd (n=215), adding a inhibitor to platinum-based chemotherapy significantly improved overall (HR: 0.36, 95% CI: 0.21─0.62) 0.35, 0.23─0.53). In p53abn cancer, significant was observed 0.71, 0.53–0.94; n=326), but no 0.80, 0.34–1.84; n=135). NSMP benefits for 0.97, 0.39–2.43; n=242) 0.44–1.44; n=373), latter affected by heterogeneity. Insufficient data available POLEmut (n=12), events reported two out majority (n=11).ConclusionPD-(L)1 inhibition demonstrated showed potential benefit, while such not found. although rare metastatic settings, associated favorable prognosis regardless treatment. These findings underscore relevance classification highlight importance prioritizing analyses guide personalized strategies.

Язык: Английский

---

Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis

BMC Cancer, Год журнала: 2024, Номер 24(1)

Опубликована: Ноя. 6, 2024

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer characterized by high rates of metastasis. Emerging evidence suggests that PD-L1/PD1 blockade holds promise as therapeutic option for MCC. However, the efficacy safety this approach in treating MCC remain incompletely understood. This systematic review meta-analysis aims to analyze PD-1/PD-L1 patients with PubMed, Cochrane, Embase were searched studies evaluating undergoing treatment. The estimated outcomes overall response rate (ORR), disease control (DCR), progression-free survival (PFS), (OS), treatment-related adverse events (TRAEs). We performed using RStudio v4.4.2 software. A total 14 reports 13 different encompassing 615 included. median age ranged from 64 77 years. Median follow-up 7.9 months 59.3 months. Pooled OS at 24 36 65.05% (95% CI 44.04–81.49) 59.58% 39.62–76.81), respectively, while pooled PFS 6, 12, 51.78% 37.83–65.45), 46.12% 29.44–63.72), 28.73% 16.57–45.02), same order. DCR proportion was 61.65% 54.85–68.03) ORR 53.79% 47.80-59.68). frequency TRAEs any grade 61.72% 45.75–75.51) ≥ 3 17.60% 12.28 24.57). revealed treatment PD-1/PDL-1 showed durable responses continuous clinically meaningful outcomes.

Язык: Английский

---

The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients

BMC Cancer, Год журнала: 2024, Номер 24(1)

Опубликована: Июнь 10, 2024

Язык: Английский

---